Topic

The long-term impact of anti-VEGF therapy for DME

A review of real-world evidence that examines the extended effectiveness of treatment.

Four ASRS abstracts look at ANX007, pegcetacoplan, encapsulated cell therapy and tarcocimab.

Standout Retina Subspecialty Day 2022 talks include real-world faricimab and high-dose aflibercept results, and Protocol T outcomes.

Why pars plana vitrectomy has come of age for vitreous opacities in selected patients.

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Three experts from Canada, Switzerland and Israel provide insights into the nuances of adherence, treatment intervals and emerging therapies.

Here’s why we should feel more confident observing patients with center-involving diabetic macular edema with good vision.

A look at chemical and biologic agents queued this year or next for key steps toward commercialization.

How quantitative assessment of perfusion and leakage dynamics may help direct management of retinal vascular disease.